Vera Therapeutics (VERA) Competitors

Vera Therapeutics logo
$26.97 -1.13 (-4.02%)
Closing price 04:00 PM Eastern
Extended Trading
$27.70 +0.73 (+2.71%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

VERA vs. KRYS, ARWR, PRAX, CYTK, and ABVX

Should you buy Vera Therapeutics stock or one of its competitors? Vera Therapeutics's main competitors and comparable companies include Krystal Biotech (KRYS), Arrowhead Pharmaceuticals (ARWR), Praxis Precision Medicines (PRAX), Cytokinetics (CYTK), and Abivax (ABVX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vera Therapeutics compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Krystal Biotech presently has a consensus price target of $375.00, suggesting a potential upside of 22.86%. Vera Therapeutics has a consensus price target of $74.93, suggesting a potential upside of 166.65%. Given Vera Therapeutics' higher possible upside, analysts clearly believe Vera Therapeutics is more favorable than Krystal Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Krystal Biotech
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
2.93
Vera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.80

Krystal Biotech has a net margin of 47.91% compared to Vera Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 17.02% beat Vera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Krystal Biotech47.91% 17.02% 15.48%
Vera Therapeutics N/A -90.03%-70.54%

In the previous week, Vera Therapeutics had 10 more articles in the media than Krystal Biotech. MarketBeat recorded 13 mentions for Vera Therapeutics and 3 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 0.89 beat Vera Therapeutics' score of 0.82 indicating that Krystal Biotech is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Krystal Biotech
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vera Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Krystal Biotech has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

Krystal Biotech has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Krystal Biotech$389.13M23.24$204.83M$7.3741.42
Vera TherapeuticsN/AN/A-$299.61M-$5.90N/A

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 15.9% of Vera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Krystal Biotech beats Vera Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Vera Therapeutics compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Arrowhead Pharmaceuticals currently has a consensus target price of $98.93, indicating a potential upside of 107.05%. Vera Therapeutics has a consensus target price of $74.93, indicating a potential upside of 166.65%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vera Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arrowhead Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.73
Vera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.80

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Arrowhead Pharmaceuticals had 8 more articles in the media than Vera Therapeutics. MarketBeat recorded 21 mentions for Arrowhead Pharmaceuticals and 13 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.82 beat Arrowhead Pharmaceuticals' score of -0.02 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arrowhead Pharmaceuticals
3 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Vera Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vera Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -160.64%. Vera Therapeutics' return on equity of -90.03% beat Arrowhead Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Arrowhead Pharmaceuticals-160.64% -172.62% -37.51%
Vera Therapeutics N/A -90.03%-70.54%

Arrowhead Pharmaceuticals has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Vera Therapeutics has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$450.82M14.93-$724.21M-$2.25N/A
Vera TherapeuticsN/AN/A-$299.61M-$5.90N/A

Summary

Vera Therapeutics beats Arrowhead Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Vera Therapeutics compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk.

Praxis Precision Medicines' return on equity of -29.41% beat Vera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Praxis Precision MedicinesN/A -29.41% -28.19%
Vera Therapeutics N/A -90.03%-70.54%

Praxis Precision Medicines has a beta of 2.85, indicating that its stock price is 185% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by company insiders. Comparatively, 15.9% of Vera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision MedicinesN/AN/A-$303.27M-$12.80N/A
Vera TherapeuticsN/AN/A-$299.61M-$5.90N/A

In the previous week, Praxis Precision Medicines had 20 more articles in the media than Vera Therapeutics. MarketBeat recorded 33 mentions for Praxis Precision Medicines and 13 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 0.82 beat Praxis Precision Medicines' score of 0.63 indicating that Vera Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Praxis Precision Medicines
7 Very Positive mention(s)
8 Positive mention(s)
10 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Vera Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Praxis Precision Medicines presently has a consensus price target of $631.68, indicating a potential upside of 92.51%. Vera Therapeutics has a consensus price target of $74.93, indicating a potential upside of 166.65%. Given Vera Therapeutics' higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Praxis Precision Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Praxis Precision Medicines
2 Sell rating(s)
1 Hold rating(s)
16 Buy rating(s)
3 Strong Buy rating(s)
2.91
Vera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.80

Summary

Praxis Precision Medicines and Vera Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Vera Therapeutics compare to Cytokinetics?

Vera Therapeutics (NASDAQ:VERA) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

In the previous week, Vera Therapeutics had 1 more articles in the media than Cytokinetics. MarketBeat recorded 13 mentions for Vera Therapeutics and 12 mentions for Cytokinetics. Vera Therapeutics' average media sentiment score of 0.82 beat Cytokinetics' score of 0.81 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vera Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cytokinetics
5 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vera Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

99.2% of Vera Therapeutics shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Vera Therapeutics has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vera TherapeuticsN/AN/A-$299.61M-$5.90N/A
Cytokinetics$113.29M69.02-$784.96M-$6.04N/A

Vera Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -686.63%. Cytokinetics' return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Vera TherapeuticsN/A -90.03% -70.54%
Cytokinetics -686.63%N/A -48.26%

Vera Therapeutics currently has a consensus target price of $74.93, suggesting a potential upside of 166.65%. Cytokinetics has a consensus target price of $106.67, suggesting a potential upside of 90.04%. Given Vera Therapeutics' higher probable upside, analysts clearly believe Vera Therapeutics is more favorable than Cytokinetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.80
Cytokinetics
1 Sell rating(s)
1 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86

Summary

Vera Therapeutics beats Cytokinetics on 11 of the 16 factors compared between the two stocks.

How does Vera Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

47.9% of Abivax shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Vera Therapeutics had 8 more articles in the media than Abivax. MarketBeat recorded 13 mentions for Vera Therapeutics and 5 mentions for Abivax. Abivax's average media sentiment score of 1.13 beat Vera Therapeutics' score of 0.82 indicating that Abivax is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abivax
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vera Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Abivax is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbivaxN/AN/A-$380.27M-$6.06N/A
Vera TherapeuticsN/AN/A-$299.61M-$5.90N/A

Abivax currently has a consensus target price of $155.00, indicating a potential upside of 76.98%. Vera Therapeutics has a consensus target price of $74.93, indicating a potential upside of 166.65%. Given Vera Therapeutics' higher probable upside, analysts clearly believe Vera Therapeutics is more favorable than Abivax.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abivax
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88
Vera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.80

Abivax has a beta of 1.36, indicating that its stock price is 36% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Vera Therapeutics' return on equity of -90.03% beat Abivax's return on equity.

Company Net Margins Return on Equity Return on Assets
AbivaxN/A -91.69% -71.96%
Vera Therapeutics N/A -90.03%-70.54%

Summary

Vera Therapeutics beats Abivax on 9 of the 13 factors compared between the two stocks.

Get Vera Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VERA vs. The Competition

MetricVera TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.09B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E Ratio-4.5726.5532.9127.37
Price / SalesN/A16.058.595.73
Price / CashN/A26.3721.9322.50
Price / Book5.844.074.403.70
Net Income-$299.61M-$22.86M$3.52B$392.17M
7 Day Performance-11.89%-7.26%-5.34%-4.53%
1 Month Performance-3.26%-4.96%-3.61%-5.86%
1 Year Performance-4.87%-2.87%0.01%-7.78%

Vera Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VERA
Vera Therapeutics
3.9702 of 5 stars
$26.97
-4.0%
$74.93
+177.8%
-0.9%$2.09BN/AN/A362
KRYS
Krystal Biotech
3.7126 of 5 stars
$303.06
+0.7%
$375.00
+23.7%
+48.1%$9.21B$389.13M42.18295
ARWR
Arrowhead Pharmaceuticals
2.9457 of 5 stars
$49.24
-15.3%
$99.07
+101.2%
+15.8%$8.68B$829.45MN/A711
PRAX
Praxis Precision Medicines
2.918 of 5 stars
$332.97
+19.9%
$630.42
+89.3%
+76.0%$7.95B$8.55MN/A168
CYTK
Cytokinetics
3.066 of 5 stars
$55.14
+2.7%
$106.67
+93.4%
-15.5%$7.91B$88.04MN/A673

Related Companies and Tools


This page (NASDAQ:VERA) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners